Niagen Bioscience (stock code: NAGE) recently announced its financial results for fiscal year 2025, delivering an impressive performance.

The company's net sales reached $129.4 million, representing a significant 30% increase compared to the same period last year. In terms of profitability, there was an even more remarkable leap, with net profit recorded at $17.4 million, soaring 103% year-on-year. Based on basic earnings per share, the company achieved earnings of $0.22 per share in fiscal year 2025. This strong growth momentum was mainly driven by sustained robust demand for core products in the market and a significant improvement in the company's operational efficiency.